In Brief
Melatonin affects the differentiation and function of effector and regulatory T cells in vitro and in vivo, representing an environmental cue that contributes to the seasonality of multiple sclerosis relapses and a potential target for therapeutic intervention in immune-mediated diseases.
INTRODUCTION
Multiple sclerosis (MS) is an immune-mediated disease of the CNS that is thought to result from the destruction of myelin by autoreactive T cells. CD4 + T cells characterized by the production of IFN-g (Th1 cells) or IL-17 (Th17 cells) are considered important contributors to MS immunopathogenesis (Miossec et al., 2009; Sospedra and Martin, 2005; Steinman, 2014) . FoxP3 + regulatory T cells (Tregs) and IL-10-secreting type 1 regulatory T cells (Tr1) regulate the activity of effector T cells, accordingly, deficits in Tregs and Tr1 cells have been described in MS (Astier et al., 2006; Sakaguchi et al., 2010; Viglietta et al., 2004) . Thus, the balance between effector and regulatory T cells controls MS disease activity (Miossec et al., 2009; Sospedra and Martin, 2005; Steinman, 2014) . Genetic polymorphisms have been associated with MS risk and/or pathogenesis (Beecham et al., 2013; Sawcer et al., 2011) . However, environmental factors such as infections (Ascherio et al., 2001; Correale and Farez, 2007; Correale et al., 2006) , sodium intake (Farez et al., 2014) , smoking (Herná n et al., 2005) , and vitamin D levels (Ascherio et al., 2014) are also known to affect MS development and course. Lower levels of vitamin D, for example, are associated with higher relapse rates (Runia et al., 2012; Simpson et al., 2010) . As a result of the regulation of its synthesis by sun exposure, a significant seasonal fluctuation on vitamin D levels is observed in most locations, with a peak in spring-summer and a nadir in autumn and winter (Rosecrans and Dohnal, 2014) . Thus, based on the reported antiinflammatory effects of vitamin D (Correale et al., 2009) (Ascherio et al., 2010) , MS relapse occurrence is predicted to peak during autumn and winter. However, several studies, including a metaanalysis (Jin et al., 2000) and a recent multicentric study (Spelman et al., 2014) found that MS disease activity is higher in spring and summer, suggesting that additional factors play a role in MS relapse seasonality.
Here, we report that melatonin levels, which peak in autumnwinter, show an inverse correlation with clinical disease activity in MS patients. Moreover, melatonin limits the development of experimental autoimmune encephalitis (EAE) and controls Th17 and Tr1 cell differentiation. Thus, seasonal changes in melatonin levels may contribute to the decreased disease activity observed in autumn and winter through a mechanism mediated, at least partially, by the regulation of effector and regulatory T cells.
RESULTS

Melatonin Levels Are Negatively Correlated with MS Clinical Relapses
We first established the seasonality of MS relapses in our cohort of 139 relapsing remitting MS patients (Table 1) . Using a Poisson regression model, we detected a 32% reduction in the number of relapses occurring during fall and winter (incidence rate-ratio [IRR] 0.682, 95% confidence interval [CI] 0.49-0.95, p = 0.02). Hence, the MS patient cohort used in this study shows the seasonality of MS relapses previously described for other cohorts (Jin et al., 2000; Spelman et al., 2014) .
Melatonin production is stimulated by darkness and follows a seasonal pattern with higher levels during fall and winter (Brzezinski, 1997) . Melatonin impacts several biological processes, including the circadian clock and the immune response (Brzezinski, 1997) . Thus, we investigated the relationship between melatonin and MS disease activity by measuring 6-sulfatoxymelatonin (6-SM) levels in relapsing-remitting MS patients. Since 6-SM is the main melatonin metabolite, its levels in first morning urine are strongly correlated with nighttime melatonin secretion, supporting its use in epidemiological studies (Graham et al., 1998; McMullan et al., 2013) . In agreement with previous reports (Morera and Abreu, 2007; Ueno-Towatari et al., 2007) , we detected increased melatonin secretion during fall and winter, with lower levels during spring and summer ( Figure 1A ; Table  1 ). Moreover, we found a significant negative correlation between 6-SM levels and MS exacerbation rates (p < 0.01 Spearman's correlation). This was further confirmed in an age and gender-adjusted Poisson regression model, with a 3% reduction in the number of relapses for each 6-SM unit increase (IRR 0.97, p = 0.007) . Finally, to test whether the relationship between melatonin levels and exacerbation rate was synchronous, we lagged the occurrence of relapses for 1 (IRR 1.01, 95% CI 0.97-1.05; p = 0.7), 2 (IRR 1.03, 95% CI 0.99-1.07; p = 0.1), and 3 months (IRR 1.03, 95% CI 0.99-1.07; p = 0.7), with no evidence of a lagged effect in relapse occurrence.
We also assessed vitamin D levels and, as previously reported for healthy controls and MS patients in our region (Correale et al., 2009; Fassi et al., 2003) , overall levels were low throughout the year with higher levels during summer but no significant correlation with MS relapses ( Figure 1B) . Finally, we did not detect a correlation between MS relapses and additional environmental factors such as reported upper respiratory tract infections and UV incidence, as determined by national registries and NASA satellites, respectively ( Figures 1C and 1D) . Thus, higher melatonin levels during fall and winter are associated with a reduction in clinical relapses.
Melatonin Ameliorates Experimental Autoimmune Encephalitis
Based on our epidemiological findings, we studied the effects of melatonin on CNS inflammation using the EAE model of MS. Naive C57BL/6 wild-type mice were immunized with MOG 35-55 and treated daily with melatonin (5 mg/kg, intraperitoneally) or vehicle. Melatonin administration ameliorated EAE clinical symptoms (Figures 2A and S1A ; Table S1 ). The amelioration of EAE was associated with a decreased number and frequency of Th17 cells in spleen, lymph nodes, and CNS; this decrease was also detected in IL-17 + IFNg + and IL-17 + GM-CSF + CD4 + T cells that have been associated to the pathogenesis of EAE (Codarri et al., 2011; El-Behi et al., 2011; Lee et al., 2012) (Figures 2C and 2D) . We also detected a concomitant increase in IL-10 secreting CD4 + T cells; no significant changes were detected in the number or frequency of other T cell subsets, B cells, gd T cells, or innate lymphoid cells (ILCs) (Figures 2B and S1B-S1D).
To further characterize the effects of melatonin on the encephalitogenic T cell response, we analyzed the recall response to MOG . Splenocytes from melatonin-treated mice showed a diminished proliferative response to MOG , reduced IL-17 concomitant with increased IL-10 production, however, no significant effects were detected on IFN-g production (Figures 2E and 2F) . Thus, melatonin arrests the encephalitogenic Th17 cell response.
To investigate if melatonin acts directly on T cells or whether it controls the T cell response indirectly through its effects on antigen presenting cells, we co-incubated sorted CD4 + T cells from melatonin-treated or control mice with treatment-switched dendritic cells (DCs). When compared to controls isolated from vehicle-treated mice, CD4 + T cells from melatonin-treated mice co-incubated with splenic DCs isolated from control mice showed decreased proliferation and IL-17 secretion, concomitant with increased IL-10 production, (Figures 2G and 2H) . Conversely, we did not detect significant differences when we used DCs isolated from melatonin or vehicle-treated mice to activate CD4 + T cells from control-treated mice.
In support for a direct effect of melatonin on T cells, melatonin suppressed the in vitro activation of naive 2D2 + transgenic T cells with MOG and DCs (Figures 2I and S1E) or with antibodies to CD3 and CD28 in the absence of DCs ( Figure 2J ). Pretreatment of DCs with melatonin did not affect their ability to activate 2D2 + T cells in the presence of MOG 35-55 ( Figure 2K ). Melatonin did not increase apoptosis in CD4 + T cells stimulated with antibodies against CD3 and CD28, as indicated by the analysis of annexin V and propidium iodide staining by flow cytometry or the expression of Bcl-xl levels (Figures S1F and S1G). IL-10 blockade, however, abrogated the suppressive effects of melatonin on T cell proliferation ( Figure S1H ).
Melatonin Affects Human T Cell Differentiation
We then studied the effects of melatonin on human CD4 + T cells.
In addition, we also analyzed the effects of agomelatine, which activates melatonin-dependent signaling (Hickie and Rogers, 2011) . Based on the effects of melatonin administration on T cells during EAE, we focused our studies on human Th17 and Tr1 cells. Melatonin and agomelatine reduced the production of IL-17, RORC, and IL17A expression by human CD4 + T cells activated under Th17 polarizing conditions (Figures 3A-3C and S2), no effect was detected on the differentiation of human Th1 cells ( Figures 3D-3F 
Melatonin Interferes with Th17 Generation
Together with Th1 cells, Th17 cells promote the development of EAE and are thought to contribute to MS pathogenesis (Lee et al., 2012) . Melatonin also increased the expression of IL-10, associated to non-pathogenic Th17 cells (Lee et al., 2012; McGeachy et al., 2007) (Figures 4A and 4B) . IFNg and IL-2 have been shown to limit Th17 cell differentiation ). However, in our studies Th17 cells were differentiated in the presence of IFNg-blocking antibodies, and IL-2 blocking antibodies failed to abrogate the suppression of Th17 differentiation by melatonin ( Figure S4A and S4B). Thus, melatonin suppresses Th17 cell differentiation through a mechanism independent of IFNg or IL-2.
Physiological concentrations of melatonin result in the activation of signaling pathways controlled by membrane and nuclear receptors (Brzezinski, 1997) . The melatonin membrane receptor MTNR1A is expressed by a variety of tissues including cells of the immune system (Jockers et al., 2008; Pozo et al., 1997) . In addition, melatonin binds to the nuclear retinoid-related orphan receptor alpha (ROR-a), which is also expressed by immune cells (Pozo et al., 2004) and plays a role in Th17 development (Yang et al., 2008) . We detected the expression of both MTNR1A and ROR-a on Th17 cells ( Figures S4C and S4D ). To study the role of MTNR1A signaling on the effects of melatonin on Th17 cells, we used the MTNR1A-specific agonists agomelatine and ramelteon (Karim et al., 2006) (Figure S4E ). Similar to our observations with melatonin, MTNR1A activation by agomelatine or ramelteon suppressed the differentiation of Th17 cells ( Figures 4C, 4D , S4F, and S4G). Conversely, melatonin failed to suppress the differentiation of MTNR1A-deficient (MTNR1A KO) Th17 cells (Figures 4E and 4F) . Thus, MTNR1A mediates the suppressive effects of melatonin on Th17 cell differentiation.
Melatonin Suppresses Th17 Cell Differentiation via Erk1/2 and C/EBPa Activation REV-ERBa (encoded by nr1d1) is a component of the circadian clock that promotes Th17 differentiation by limiting the expression of NFIL3, a direct inhibitor of rorc transcription (Yu et al., 2013) . Melatonin regulates the activity of both circadian and seasonal clocks (Pé vet, 2003) . Indeed, melatonin levels show a circadian inverse correlation with nr1d1 expression, suggesting that melatonin affects REV-ERBa expression (Kojetin and Burris, 2014) . Thus, we investigated whether melatonin acts on REVERBa to suppress Th17 cell differentiation.
Using reverse protein arrays (Farez et al., 2009) we analyzed signaling pathways triggered by melatonin in T cells and detected an MTNR1A-dependent increase in the activation of Erk1/2 ( Figures 4G, 4H , S4H, and S4I). Of note, Erk1/2 inhibition has been previously shown to enhance Th17 cell differentiation (Tan and Lam, 2010) and Erk1/2 phosphorylation has been linked to the reduced expression of REV-ERB proteins (Castellano et al., 2014; Kojetin and Burris, 2014) , but the mechanism involved and its relevance for T cells has not been characterized yet. Through a bioinformatic analysis of the nr1d1 promoter, we identified a binding site for the CAAT/enhancer-binding protein a (C/EBPa), a leucine zipper transcription factor involved in the regulation of cellular differentiation (Lekstrom-Himes and Xanthopoulos, 1998). C/EBPa is a downstream target of Erk1/2 activated by phosphorylation (Johnson, 2005) . Thus, we analyzed whether Erk1/2 regulates the transcriptional activity of the nr1d1 promoter in a C/EBPa-dependent manner.
Th17 cell differentiation in the presence of melatonin led to C/EBPa phosphorylation and the recruitment of C/EBPa to the nr1d1 promoter (Figures 4I and 4J) . C/EBPa phosphorylation and recruitment to the nr1d1 promoter were suppressed in MTNR1A KO T cells and in the presence of the Erk1/2 inhibitor UO216 ( Figures 4I and 4J ). Hence, melatonin triggers the recruitment of C/EBPa to the nr1d1 promoter in an MTNR1A-and Erk1/ 2-dependent manner.
To analyze the effects of C/EBPa on the transcriptional activity of the nr1d1 promoter, we used a reporter construct in which the nr1d1 promoter controls luciferase expression. Treatment of nr1d1 reporter-transfected HEK293 cells with melatonin or agomelatine resulted in decreased luciferase activity and similar See also Figure S1 and Table S2. effects were achieved by C/EBPa overexpression ( Figure 4K ). Finally, to investigate the role of C/EBPa on the suppression of Th17 cell differentiation by melatonin we used C/EBPa-deficient T cells (Yang et al., 2005) . C/EBPa-deficiency abrogated the decrease in nr1d1 expression and the suppression of Th17 differentiation induced by melatonin ( Figures 4L and 4M ). Thus, melatonin suppresses the differentiation of Th17 cells through a mechanism mediated by MTNR1A, Erk1/2, and C/EBPa.
Melatonin Inhibits ROR-gt and ROR-a Expression in Th17 Cells by Inducing Nfil3
NFIL3 limits Th17 cell differentiation by suppressing the expression of ROR-gt (Yu et al., 2013) . REV-ERBa inhibits nfil3 expression (Yu et al., 2013) . Thus, we hypothesized that the decrease in nr1d1 expression induced by melatonin results in the NFIL3-dependent inhibition of rorc expression ( Figure 5A ). We detected nr1d1 expression in Th17 cells, but not in Th0 or Tr1 cells (Figure 5B) . Melatonin suppressed nr1d1 expression during Th17 cell differentiation, resulting in a concomitant increase in the expression of the ROR-gt repressor NFIL3 ( Figures 5C and  5D ). In agreement with our results on Th17 cell differentiation, the regulation of REV-ERBa and NFIL3 expression by melatonin was mediated by its membrane receptor MTNR1A and Erk1/2 ( Figures 5C-5G ). The relevance of the regulation of REV-ERBa expression for the modulation of Th17 cell differentiation by melatonin was confirmed in nr1d1 overexpression experiments and by the use of REV-ERBa-deficient T cells. Nr1d1 overexpression and REV-ERBa deficiency abrogated the effects of melatonin on Th17 cell differentiation ( Figures 5H-5K ). Hence, MTNR1A-dependent signaling triggered by melatonin suppresses Th17 cell differentiation through the regulation of REVERBa expression. ROR-a promotes Th17 cell differentiation (Yang et al., 2008) . Accordingly, ROR-a activation by the specific agonist CGP 52608 boosted Th17 cell differentiation ( Figures 4C and 4D ). ROR-a is directly activated by melatonin (Brzezinski, 1997) . Indeed, melatonin boosted the differentiation of MTNR1A-deficient Th17 cells ( Figure 4E ), suggesting that melatonin-triggered MTNR1A signaling interferes with the promotion of Th17 cell differentiation by ROR-a. Based on the inhibitory effects of NFIL3 on ROR-gt expression and Th17 cell differentiation (Yu et al., 2013) , we studied whether NFIL3 also inhibits ROR-a expression.
A bioinformatics analysis identified NFIL3 binding sites in the rora and rorc promoters. Accordingly, we detected the recruitment of NFIL3 to the rora and rorc promoters in CD4 + T cells activated under Th17 polarizing conditions in the presence of melatonin, concomitant with a reduced expression of both ROR-a and ROR-gt ( Figures 5L and 5M ). We then investigated the relevance of the regulation of NFIL3 expression for the modulation of Th17 cell differentiation. Overexpression of NFIL3 ( Figures 5N  and 5O ) and NFIL3-deficiency ( Figures 5P and 5Q ) abrogated the suppressive effects of melatonin on Th17 cell differentiation. Thus, the regulation of NFIL3 expression by melatonin mediates its inhibitory effects on the differentiation of Th17 cells in vitro. To evaluate the role of MTNR1A and NFIL3 on the suppression of Th17 cell differentiation by melatonin in vivo, we used RAG-1-deficient mice reconstituted with wild-type, MTNR1A-, REVERBa-, or NFIL3-deficient CD4 + T cells and immunized with MOG 35-55 in CFA. In agreement with our in vitro observations, the suppression of Th17 cell differentiation by melatonin in vivo was abrogated by MTNR1A-, REV-ERBa-, and NFIL3-deficiency ( Figures 5R and S5 ). Indeed, we detected increased Th17 cell differentiation in response to treatment of mice reconstituted with MTNR1A-, REV-ERBa-, or NFIL3-deficient T cells, most likely reflecting the unopposed agonistic activity of melatonin on ROR-a and its promoting effects on the differentiation of Th17 cells. Taken together, these data suggest that melatonin interferes with Th17 cell differentiation via the inhibition of ROR-gt and ROR-a expression through an NFIL3-dependent mechanism.
Melatonin Boosts Tr1 Cell Differentiation via Erk1/2 and ROR-a CD4 + IL-10-producing Tr1 cells play an important role in the regulation of the immune response (Pot et al., 2011; Roncarolo et al., 2006) . The amelioration of EAE by melatonin administration was associated with an increase in IL-10-producing T cells (Figure 2) . Thus, we investigated the effects of melatonin on the activation of naive CD4 + T cells under Tr1 polarizing conditions. We found that melatonin boosted the expression of IL-10 and the Tr1-associated molecules il21, ahr, and cmaf (Apetoh et al., 2010 ) ( Figure 6A ). In addition, melatonin boosted the suppressive activity of Tr1 cells in vitro ( Figure 6B ). We then investigated the mechanisms underlying the effects of melatonin on Tr1 regulatory cells. We detected the expression of both MTNR1A and ROR-a by Tr1 cells (Figures S4C and S4D) . Indeed, both agomelatine and CGP 52608, specific agonist for MTNR1A and ROR-a, respectively, boosted Tr1 cell differentiation ( Figures 6C and 6D ). In agreement with these results, MTNR1A deficiency or inhibition of MTNR1A-activated Erk1/2 by UO126 interfered with the boost in Tr1 differentiation by melatonin ( Figures 6E and 6F ). Of note, Erk1/2 activation is reported to promote cmaf-dependent IL-10 production by CD4 + T cells (Saraiva et al., 2009 ). In addition, ROR-a deficiency suppressed the differentiation of Tr1 cells induced by IL-27 and its boost by melatonin ( Figure 6G ). ROR-a exerts its biological effects by binding to ROR response elements (ROREs) in target genes (Jetten, 2009) . A bioinformatic analysis identified ROR-a binding sites in the il10 promoter ( Figure 6H ), suggesting that melatonin may increase the recruitment of ROR-a to the il10 promoter and consequently, il10 transcription. In agreement with this hypothesis, we detected increased binding of ROR-a to the il10 promoter following T cell activation under Tr1 polarizing conditions in the presence of melatonin ( Figure 6H ). Moreover, ROR-a transactivated the il10 promoter in reporter assays and synergized with the aryl hydrocarbon receptor (AhR) and c-Maf to boost their ability to promote il10 expression (Apetoh et al., 2010; Gandhi et al., 2010) ( Figure 6I ). Taken together, these data suggest that melatonin boosts Tr1 cell differentiation through its effects on MTNR1A and ROR-a ( Figure 6J ).
DISCUSSION
Strong epidemiological evidence supports the role of vitamin D in reducing MS relapses (Ascherio et al., 2012) . Strikingly, vitamin D levels are higher during spring and summer, when relapse occurrence in MS patients peaks. Thus, the observation of a lower occurrence of relapses in seasons characterized by lower vitamin D levels represents a ''seasonal paradox'': relapses should be less frequent in spring and summer when vitamin D levels are higher, yet the opposite is found in most studies (Jin et al., 2000; Spelman et al., 2014) , with a few exceptions (Løken-Amsrud et al., 2012) . Our data may solve this paradox by identifying melatonin, whose levels are regulated by seasonal fluctuations in day length, as an additional regulator of the immune response in MS. Note that night shift work, which is associated with lower overall melatonin levels (Schernhammer et al., 2004) , increases the risk of developing MS (Hedströ m et al., 2011) . These findings suggest that melatonin may also be an MS risk factor; the relationship between melatonin levels and the risk of developing MS is the focus of ongoing investigations. Finally, the interplay between melatonin and other seasonal environmental factors known to impact MS such as vitamin D in different geographic locations remains to be further elucidated.
The rise in the past 50 years in the incidence of autoimmune disorders has reached an epidemic proportion and cannot be accounted by genetic risk only. Thus, increasing attention is being paid to environmental factors and their impact in the immune response and T cell differentiation in particular. For example: several compounds present in household products can activate the aryl hydrocarbon receptor and impact both Th17 and regulatory cell differentiation (Quintana et al., 2008) ; sodium in westernized diet and processed foods can also enhance Th17 cell differentiation (Wu et al., 2013) ; the composition of commensal microbiota impacts T cell differentiation and response (Lathrop et al., 2011) ; and the lack of sun exposure and dietary habits can diminish vitamin D levels and affect regulatory cell function (Correale et al., 2009 ). Each of these environmental factors trigger different signaling pathways and the characterization of the complex interaction between them can shed light on the impact of the environment on the immune system. See also Figure S5 . Pro-inflammatory Th17 cells are thought to contribute to the pathogenesis of EAE and MS (Miossec et al., 2009 ). Th17 cell differentiation is regulated by ROR-a and ROR-gt and therapies targeting Th17 cells are currently being tested in MS and other autoimmune diseases with preliminary encouraging results (Baeten and Kuchroo, 2013) . Melatonin, despite having the potential to activate ROR-a, suppresses the generation of Th17 cells via its membrane receptor in a NFIL3-dependent fashion. Interestingly, it has been recently shown that the circadian clock suppresses Th17 development during nighttime through a similar NFIL3-dependent mechanism (Yu et al., 2013) . Our work suggests that, in addition to Th17 cells, Tr1 cells are also regulated by melatonin during nighttime in an Erk1/2-and ROR-a-dependent manner. Based on the high evolutionary conservation of melatonin production by the pineal gland and its regulation by daylight (Macchi and Bruce, 2004) , it is likely that the circadian and seasonal effects of melatonin on the immune response play an important role that resulted in its positive selection during evolution.
Tr1 cells are characterized by the production of IL-10 (Pot et al., 2011; Roncarolo et al., 2006) . AhR, c-Maf, and Erk1/2 have been shown to regulate Tr1 cell development and IL-10 expression (Apetoh et al., 2010; Gandhi et al., 2010) . Our work shows that melatonin promotes Tr1 cell differentiation by activating Erk1/2 signaling, which has been previously described to control IL-10 expression in T cells and DCs (Saraiva and O'Garra, 2010) . We also identified ROR-a as a mediator of the effects of melatonin in Tr1 cells. Thus, these data suggest that melatonin utilizes multiple pathways to boost Tr1 cell differentiation.
The interplay between pro-inflammatory and regulatory cells controls the development of autoimmune diseases such as MS. Here, we report that melatonin, whose levels show seasonal variability, control the balance between pathogenic and regulatory T cells. However, in MS patients, melatonin is likely to act on several cell types to affect disease activity. Indeed, NFIL3 has been shown to play a role in human inflammatory bowel disease and autoimmune colitis through its activity on innate immune cells (Kobayashi et al., 2014) . Thus, future studies should investigate the effects of melatonin on innate immune cells in MS patients and also its role in inflammatory bowel disease and other immune-mediated disorders. Finally, although our data identify melatonin-dependent signaling as a potential target for therapeutic immunomodulation, the pathways involved are complex and likely cross-regulated. Thus, extreme caution should be exercised to evaluate the translational potential of these findings.
EXPERIMENTAL PROCEDURES Patients
Consecutive patients with relapsing-remitting MS according to McDonald criteria (Polman et al., 2011) were recruited from the MS clinic at the Raú l Carrea Institute for Neurological Research (FLENI) between September of 2011 and November of 2012. Study protocol was approved by the Institutional Ethics Committee, and all subjects signed an informed consent form. See Supplemental Experimental Procedures for detailed information.
Animals and EAE
EAE was induced as follows: mice were immunized with 100 mg MOG and 500 mg mycobacterium tuberculosis extract H37Ra (Difco). Mice were also injected intraperitoneally with 200 ng pertussis toxin on days 0 and 2. Melatonin (5 mg/kg) or vehicle (0.01% DMSO) was administered daily at 7:00 p.m.
Flow Cytometry Staining and Acquisition
For intracellular cytokine staining, cells were stimulated for 4 hr at 37 C with phorbol 12-myristate 13-acetate (50 ng/ml; Sigma), ionomycin (1 mg/ml; Sigma), and monensin (GolgiStop; 1 mg/ml; BD Biosciences). After being stained for surface markers, cells were fixed and made permeable according to the manufacturer's instructions (BD Biosciences). All antibodies against cytokines were from Biolegend. All experiments were started at the same time (8:00-9:00 a.m.). Data were collected with a LSR II or FACSAria (BD Biosciences), then were analyzed with FlowJo software (Treestar).
Measurement of Cytokines
Secreted cytokines were measured in tissue culture supernatants after 72-96 hr by ELISA as previously described (Farez et al., 2009 ).
qRT-PCR RNA was extracted with RNAeasy columns (QIAGEN), then cDNA was prepared according to the manufacturer's instructions (Applied Biosystems) and was used as template for real-time PCR. All primers and probes were provided by Applied Biosystems and were used on the ViiA 7 Real-Time PCR System (Applied Biosystems). Expression was normalized to the expression of the housekeeping gene Gapdh.
Immunoblot Analysis
For immunoblot analysis, cells were lysed with radio-immunoprecipitation buffer supplemented with protease inhibitor ''cocktail'' (Sigma-Aldrich). Total lysates of the different T cell subsets (40 mg) were resolved by electrophoresis through 4%-12% Bis-Tris Nupage gels (Invitrogen) and were transferred onto PVDF membranes (Millipore). The following primary antibodies were used: anti-ROR-a (Abcam), anti-MTNR1A (Santa Cruz), anti-total and phospho-Erk1/2 (Cell Signaling), anti-total C/EBP a (Cell Signaling), anti-phospho C/EBPa (Cell Signaling), anti-Nfil3 (Santa Cruz), and anti-GADPH (Abcam). Blots were developed with SuperSignal West Femto Maximum Sensitivity Substrate as suggested by the manufacturer (Pierce).
Statistical Analysis
A Poisson regression model was used to assess the impact of season 6-SM levels and the number of clinical relapses, generating an incidence rate ratio (IRR) and corresponding 95% confidence intervals (CI 
